Your browser doesn't support javascript.
loading
Mid-term assessment of structural valve deterioration of perceval S sutureless prosthesis using the last European consensus definition.
Martínez-Comendador, José Manuel; Estevez-Cid, Francisco; González Barbeito, Miguel; Velasco García De Sierra, Carlos; Bouzas Mosquera, Alberto; Barbeito, Cayetana; Cuenca Castillo, José; Herrera-Noreña, José.
Afiliação
  • Martínez-Comendador JM; Department of Cardiovascular Surgery, Hospital Universitario A Coruña, A Coruña, Spain.
  • Estevez-Cid F; Department of Cardiovascular Surgery, Hospital Universitario A Coruña, A Coruña, Spain.
  • González Barbeito M; Department of Cardiovascular Surgery, Hospital Universitario A Coruña, A Coruña, Spain.
  • Velasco García De Sierra C; Department of Cardiovascular Surgery, Hospital Universitario A Coruña, A Coruña, Spain.
  • Bouzas Mosquera A; Department of Cardiology, Hospital Universitario A Coruña, A Coruña, Spain.
  • Barbeito C; Department of Cardiology, Hospital Universitario A Coruña, A Coruña, Spain.
  • Cuenca Castillo J; Department of Cardiovascular surgery, Hospital San Rafael, A Coruña, Spain.
  • Herrera-Noreña J; Department of Cardiovascular Surgery, Hospital Universitario A Coruña, A Coruña, Spain.
Interact Cardiovasc Thorac Surg ; 32(4): 499-505, 2021 04 19.
Article em En | MEDLINE | ID: mdl-33881147
OBJECTIVES: Durability of sutureless aortic bioprosthetic valves remains a major issue. The aim of this study was to assess structural valve deterioration (SVD) and bioprosthetic valve failure (BVF) of the Perceval bioprosthesis using the new proposed standardized definitions. METHODS: All patients who underwent aortic valve replacement with sutureless Perceval S prostheses up to September 2016 were included. Clinical and echocardiographic follow-up was performed. New standardized definitions were used to assess the durability of sutureless bioprosthetic valves. From 2013 to 2016, 214 patients were included. RESULTS: The mean age and EuroSCORE II were 79 years and 2.74. Thirty-day mortality was 0.47%. The survival rate was 96.8%, 88.1% and 85.7% at 1, 3 and 4 years, respectively. The median echocardiographic follow-up was 3.28 years. The mean pressure gradient was 11.3 mmHg. No cases showed evidence of severe SVD, 17 patients had moderate SVD with a mean pressure gradient of 24 mmHg and 8 patients had definite late BVF. The incidence of moderate SVD and BVF at 4 years was 8.8% and 2.9%, respectively. CONCLUSIONS: Mid-term follow-up to 6.3 years after aortic valve replacement with the Perceval bioprosthesis documents favourable haemodynamic and clinical outcomes and low rates of SVD and BVF.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estenose da Valva Aórtica / Próteses Valvulares Cardíacas / Substituição da Valva Aórtica Transcateter Tipo de estudo: Guideline Limite: Aged / Humans Idioma: En Revista: Interact Cardiovasc Thorac Surg Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estenose da Valva Aórtica / Próteses Valvulares Cardíacas / Substituição da Valva Aórtica Transcateter Tipo de estudo: Guideline Limite: Aged / Humans Idioma: En Revista: Interact Cardiovasc Thorac Surg Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha País de publicação: Reino Unido